The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA

Enhanced expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein is frequent in cancer. Targeting of BCL-2 with the specific inhibitor ABT-199 (Venetoclax) has significant clinical activity in malignant diseases such as chronic lymphocytic leukemia and multiple myeloma. The small molecule dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, Sandra, Toennießen, Astrid, Schaefer, Benjamin, Beigl, Tobias, Muenchow, Alina, Böpple, Kathrin, Hofmann, Ute, Gillissen, Bernhard F., Aulitzky, Walter E., Kopp, Hans-Georg, Essmann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021261/
https://www.ncbi.nlm.nih.gov/pubmed/35443750
http://dx.doi.org/10.1038/s41420-022-01009-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021261/
https://www.ncbi.nlm.nih.gov/pubmed/35443750
http://dx.doi.org/10.1038/s41420-022-01009-1

Ejemplares similares